Show simple item record

dc.contributor.authorMarabelle, Aen_US
dc.contributor.authorAndtbacka, Ren_US
dc.contributor.authorHarrington, Ken_US
dc.contributor.authorMelero, Ien_US
dc.contributor.authorLeidner, Ren_US
dc.contributor.authorde Baere, Ten_US
dc.contributor.authorRobert, Cen_US
dc.contributor.authorAscierto, PAen_US
dc.contributor.authorBaurain, J-Fen_US
dc.contributor.authorImperiale, Men_US
dc.contributor.authorRahimian, Sen_US
dc.contributor.authorTersago, Den_US
dc.contributor.authorKlumper, Een_US
dc.contributor.authorHendriks, Men_US
dc.contributor.authorKumar, Ren_US
dc.contributor.authorStern, Men_US
dc.contributor.authorÖhrling, Ken_US
dc.contributor.authorMassacesi, Cen_US
dc.contributor.authorTchakov, Ien_US
dc.contributor.authorTse, Aen_US
dc.contributor.authorDouillard, J-Yen_US
dc.contributor.authorTabernero, Jen_US
dc.contributor.authorHaanen, Jen_US
dc.contributor.authorBrody, Jen_US
dc.identifier.citationAnn Oncol, 2018, 29 (11), pp. 2163 - 2174en_US
dc.description.abstractA European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry and 2 clinicians who were representatives of ESMO. The focus of the meeting was exclusively on the intratumoral injection/delivery of immunostimulatory agents with the aim of harmonizing the standard terms and methodologies used in the reporting of human intratumoral immunotherapy (HIT-IT) clinical trials to ensure quality assurance and avoid a blurring of the data reported from different studies. The goal was to provide a reference document, endorsed by the panel members that could provide guidance to clinical investigators, pharmaceutical companies, ethics committees, independent review boards, patient advocates and the regulatory authorities and promote an increase in the number and quality of HIT-IT clinical trials in the future. Particular emphasis was placed not only on the development of precise definitions to facilitate a better understanding between investigators but also on the importance of systematic serial biopsies as a driver for translational research and the need for the recording and reporting of data, to facilitate a better understanding of the key processes involved.en_US
dc.format.extent2163 - 2174en_US
dc.titleStarting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).en_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfAnn Oncolen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.embargo.termsNot knownen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as